Glycoprotein gB of herpes simplex virus expresses type-common and type-specific antigenic determinants in vivo.
Four monoclonal antibodies directed against glycoprotein B of herpes simplex virus were evaluated for their ability to immunize mice passively against acute virus-induced neurological illness and death when administered intraperitoneally 2 hours prior to footpad challenge with type 1 or type 2 virus. Two monoclonal antibodies, H120 and H157, failed to reduce the severity of neurological disease in infected animals. In contrast, H233 and H368 antibodies provided significant protection in type-common and type-specific fashions, respectively. A direct correlation was observed between in vitro neutralization and in vivo protection. These results provide the first in vivo evidence that glycoprotein gB of herpes simplex virus expresses both type-common and type-specific determinants during the evolution of acute virus-induced neurological disease.
Dix
R D
RD
Department of Ophthalmology, University of Miami School of Medicine, Bascom Palmer Eye Institute, Florida 33101.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000939:Epitopes / Q000032:analysis*; D006561:Herpes Simplex / Q000276:immunology* / Q000517:prevention & control; D007116:Immunization, Passive; D051379:Mice; D008807:Mice, Inbred BALB C; D018139:Simplexvirus / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000939:Epitopes; D014759:Viral Envelope Proteins; C044525:glycoprotein B, herpes simplex virus type 2